Table 2. Disease and surgery characteristics.
| Variable | Never sarcopenic (N=24) (%) | Ever sarcopenic (N=12) (%) | P value |
|---|---|---|---|
| Surgical resection | 0.565 | ||
| Subtotal gastrectomy | 26.7 | 23.1 | |
| Total gastrectomy | 56.7 | 76.9 | |
| Surgical approach | 0.728 | ||
| Robotic | 20.0 | 15.4 | |
| Tumor | |||
| Tumor size | 5.75 | 7.56 | 0.540 |
| Pre-treatment AJCC T | 2.61 | 2.78 | 0.484 |
| Post-treatment AJCC T | 2.60 | 2.69 | 0.853 |
| Change in AJCC T | −0.13 | −0.11 | 0.972 |
| Lymph nodes | |||
| Number of positive LN | 4.88 | 5.92 | 0.705 |
| Pre-treatment AJCC N | 1.00 | 1.46 | 0.193 |
| Post-treatment AJCC N | 1.32 | 1.23 | 0.843 |
| Perineural invasion | 40.0 | 36.4 | 0.842 |
| Lymphovascular invasion | 62.5 | 41.7 | 0.236 |
| Surgical margins | 0.068 | ||
| Positive | 6.7 | 30.8 | |
| Negative | 76.7 | 69.2 | |
| Post-operative complication | 25.0 | 58.3 | 0.050 |
| Weight (kg) | |||
| Pre-operative | 86.26 | 72.93 | 0.168 |
| Post-operative | 77.95 | 70.42 | 0.316 |
| Weight change | −8.49 | −2.51 | 0.139 |
| Neoadjuvant chemotherapy | 0.948 | ||
| DCF | 3.3 | 7.7 | |
| ECX | 10.0 | 15.4 | |
| ECF | 43.3 | 58.9 | |
| Other | 23.3 | 23.1 |
AJCC, American Joint Committee on Cancer.